Avalon GloboCare is a small, early-stage technology holding company with two nascent business segments. The first is Keto Air, a pen-shaped, reusable breath-based device that measures whether a user is in ketosis — a metabolic state associated with low-carb diets. Avalon holds exclusive North American distribution rights for the device and sells it primarily through social media influencer marketing and a relationship with the Law Enforcement Association of America. The product is still in early-stage commercial testing. The second segment is the RPM Platform (Avalon Quantum AI), an AI-driven short-form video generation tool acquired via the purchase of RPM Interactive in December 2025 for $19.5M in preferred stock. The platform targets content creators, initially podcasters: a user inputs a topic, the platform scrapes the internet for relevant content, and produces a three-minute video featuring an AI-generated avatar that replicates the creator's voice and likeness. The platform is currently in beta and is pre-revenue. Avalon also holds a legacy portfolio of cellular therapy patents, some co-owned with MIT, which it maintains for potential licensing or sale value. The company has pivoted its business model multiple times, previously focusing on cellular therapy, a clinical laboratory investment, and a failed merger with a Hong Kong-based company. As of early 2026, Avalon employed only two full-time employees.